Eiger BioPharmaceuticals Inc (EIGRQ)
Market Cap | 4.49M |
Revenue (ttm) | 15.77M |
Net Income (ttm) | -74.96M |
Shares Out | 1.48M |
EPS (ttm) | -50.78 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,301 |
Open | 2.270 |
Previous Close | 3.798 |
Day's Range | 2.250 - 3.040 |
52-Week Range | 1.610 - 4.000 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About EIGRQ
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that... [Read more]
Financial Performance
In 2023, EIGRQ's revenue was $15.77 million, an increase of 16.98% compared to the previous year's $13.48 million. Losses were -$74.96 million, -22.54% less than in 2022.
Financial numbers in USD Financial StatementsNews
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmac...
Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone p...
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative the...
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Comp...
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare...
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare...
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workfor...
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workfo...
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
Company to host conference call and live webcast on Thursday, June 29, at 8:30 am ET PALO ALTO, Calif. , June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage...
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 Phase 3 HI AVANT (avexitide) Program: Star...
Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PALO ALTO, Calif. , May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepat...
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments
PALO ALTO, Calif., April 13, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepa...
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT ...
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical e...
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023
NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Attention Eiger BioPharmaceuticals, Inc. ("Eiger") (NASDAQ: EIGR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenc...
EIGR FINAL DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR
New York, New York--(Newsfile Corp. - January 6, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) b...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of inves...
Eiger Class Action: Levi & Korsinsky Reminds Eiger BioPharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2023 - EIGR
New York, New York--(Newsfile Corp. - January 6, 2023) - Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securiti...
DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023
NEW YORK , Jan. 6, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR). ...
MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharma...
EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS...